Business Wire

RecVue Launches First AI Native Agentic Revenue Operating System

21.7.2026 15:03:00 CEST | Business Wire | Press Release

Share

RecVue, the leader in billing and revenue management solutions, today announced the evolution of RecVue RevOS into the industry's first Agentic Revenue Operating System. In an architectural shift, the now-native agentic revenue management platform moves revenue operations beyond AI-assisted workflows to fully governed, autonomous execution with more than 50 purpose-built agents that work across contracts, invoices and payment data to predict risk, surface anomalies and escalate exceptions throughout the quote-to-cash lifecycle.

Enterprise revenue operations have long suffered from a structural gap between billing systems that generate invoices and ERP systems that record transactions. Finance teams face tedious, manual reconciliation month after month, often resulting in delayed cash, billing errors that generate disputes, revenue leakage from ungoverned contract changes and close cycles that consume weeks.

“Enterprise RevOps has always demanded both speed and precision, but traditional platforms force a trade-off between the two,” said Nishant Nair, Founder and CEO, RecVue. “RevOS is built on a fundamentally different, agentic architecture that executes in real time, at enterprise scale, with full governance and auditability built in. This is not AI added to a workflow. It’s a reasoning system that runs the revenue lifecycle, with traceability and human oversight in every action.”

Unlike past AI implementations that automated individual steps in the revenue cycle, leaving gaps for revenue to leak and close cycles to drag, RevOS connects those steps by operating as an interconnected system of agents that reason within and across five solution pillars: Contracts & Pricing, Billing & Invoicing, Receivables and Cash Management, Revenue Recognition and Revenue Share.

Governance and Traceability

RevOS was built with finance’s traceability concerns in mind. Governance isn’t an added layer; it’s built into the foundation. Every agent operates with:

  • A full audit trail traceable to the originating contract, invoice, or payment event
  • Approval checkpoints, ensuring human judgment is preserved
  • AI cost visibility and role-based access control across every workflow
  • Human-in-the-loop escalation built into agent logic

Connected Intelligence

The RevOS Portal delivers a persona-configured intelligence experience for every stakeholder in the revenue lifecycle. For the CFO, that experience is the CFO Copilot, an executive layer that reasons across all five solution pillars to surface risks, explain root causes, and suggest interventions in real time. The need to assemble revenue health from a patchwork of disconnected systems is replaced by a single conversational interface that knows the full context, from the first contract term to the last dollar collected.

“For the first time, finance leaders can ask why is my DSO 70 days and get a traceable answer, not a BI report to interpret,” Nair said.

Industry Support

“As a business, we continuously need to improve in reinforcing processes, managing risks and enhancing results," said Ingeborg Dierens, CFO, Cebeo (a Sonepar Company). "RevOS fundamentally supported in these domains is providing the tools and intelligence to our teams. AI that understands our portfolio, anticipates customer issues before they escalate, and recommends right actions at the right time is not just an operational win, it is a working capital win.”

Learn more and see RevOS live in the August 19 webinar.

About RecVue

RecVue is the Agentic Revenue Operating System (RevOS) purpose-built to power modern monetization models. Designed for today’s most complex revenue environments, RecVue unifies contracts and pricing, billing, cash management, revenue recognition, and partner compensation models into a single, AI-powered platform. With native support for usage-based, recurring, milestone, and multi-party monetization models, RecVue automates and scales the entire revenue lifecycle—from quote to cash to close—without reengineering the tech stack. RecVue integrates seamlessly with ERP and CRM systems and delivers intelligent workflows that eliminate revenue leakage, accelerate billing cycles, and ensure compliance. RecVue is used by 200+ legal entities in over 50 countries, and leading brands like Hertz, World Wide Technology, ACI Worldwide, Textainer, and Landstar. Learn more at recvue.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260716171960/en/

Contacts

Media Contact:
Kimberly Doyle
kim.doyle@recvue.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 16:50:00 CEST | Press Release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive

emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 17:12:00 CEST | Press Release

emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead

Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 15:00:00 CEST | Press Release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme

EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 15:00:00 CEST | Press Release

European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea

ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 14:00:00 CEST | Press Release

ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye